Introduction
Immunotherapy relevantly changed the treatment and the outcome in a variety of malignant diseases like melanoma, renal, bladder and lung cancer or Hodgkin's disease. In contrast, metastatic colorectal cancer (CRC) only rarely showed responses to checkpoint inhibition [1] . Deciphering these responses revealed high tumour mutational burden (TMB) as a predictive marker for response. The higher the TMB the higher the neo-antigen load and thus the higher immunogenicity was observed [2] . Interestingly,
Immunotherapy in dMMR/MSI-H MCRC

Single-Agent PD-1 Inhibitors
The KEYNOTE(KN)-016 trial of pembrolizumab reported the first interim data in dMMR/MSI-H MCRC showing an overall response rate (ORR) of 40% (n = 10), compared to 0% in mismatch repair-proficient (pMMM) or microsatellite stable (MSS) tumours (n = 18) [4] . In this trial further non-colorectal dMMR/MSI-H tumours were included leading to the first-ever agnostic (i.e. histology and tumour-site independent) approval of a cancer drug in May 2017 in the US. Finally, 40 dMMR/MSI-H MCRC patients were treated in KN-016, as part of overall 86 dMMR patients across 11 tumour types [12] .
In a cohort of the Check-Mate(CM)-142 trial, 74 patients with dMMR/MSI-H MCRC were treated with nivolumab, leading to accelerated approval of nivolumab in the US in summer 2017 [13] .
The toxicity findings in both trials of nivolumab and pembrolizumab were consistent with data from other tumour indications. Both cohorts, in line with early data for further 61 MSI-H patients from KN-164 [14] , provide the current clinical evidence for this biomarker-defined subpopulation of CRC patients. ORR in CM-142 and KN-164 was around 30% with a substantially higher rate (52%) reported for KN-016; 1-year overall survival (OS) rates were identical in all trials (73% vs. 72% vs. 76%) in these quite similar patient cohorts with about 50% of patients with 3 previous systemic therapies (table 1) .
Combination of PD-1 and CTLA-4 Inhibitors
The combination of nivolumab and ipilimumab in dMMR/ MSI-H MCRC patients was studied in a further cohort (n = 119 patients) of CM-142. Recently published results showed a relevant clinical efficacy with an ORR of 55% and a 12-weeks disease control rate-rate 80% [15] . Reponses were durable with a progressionfree survival (PFS) rate of 71% and OS rate of 85% after 1 year. The median survival times were not reached yet. Of note, responses were independent of KRAS and BRAF mutation status, tumour PD-L1 expression or clinical history of Lynch syndrome. Similar to the single-agent PD-1 inhibitor data, patients were already heavily pre-treated (76% of patients had received at least 2 prior lines of therapy for metastatic disease). Although no randomised data are currently available the OS results (1 year OS rate of 85%) compare favourably with the single-agent PD-1 inhibitor data (1 year OS rates between 72 and 76%) [12, 16] (table 1) . The toxicity profile was as expected and based on the chosen regimen with nivolumab 3 mg/kg and ipilimumab 1 mg/kg (week 1, 4, 8 and 11), followed by nivolumab every 2 weeks, the low-dose ipilimumab did not add a lot more side effects to single-agent nivolumab.
Combination of Immunotherapy and Antiangiogenic Agents
Based on the favourable results in renal cell cancer, recently preliminary results of a small cohort of 10 dMMR/MSI-H MCRC patients treated with atezolizumab and bevacizumab showed efficacy and tolerability [17] .
Immunotherapy in pMMR/MSS MCRC
Both trials leading to accelerated approval in the USA (KN-016 and CM-142) also included a cohort of pMMR/MSS CRC patients treated with either single-agent pembrolizumab (KN-016) or the combination of nivolumab and ipilimumab (CM-142) [18, 19] . In both cohorts, no or only very rarely responses were noted, thus further underlining the predictive value of dMMR/MSI-H status.
The combination of PD-1/L1 and CTLA-4 inhibitors were further evaluated in a phase I trial combining durvalumab and tremelimumab showing 2 partial responses in 18 CRC patients (ORR 11%), however, putting these data into context is difficult as MMR/ MSI status was not reported [20] .
Besides checkpoint inhibition other immunological treatment approaches have been evaluated and trials are still ongoing, such as immunomodulation with toll-like receptor 9 agonist (MGN1703) after conventional induction chemotherapy, which has shown to be efficacious in a small, randomised trial [21] . A confirmatory phase III trial is currently ongoing.
Combination Regimen in MMR/MSI Unselected or Unknown MCRC
Based on the poor efficacy of immunotherapy in the vast majority of MCRC patients with only 5% being dMMR/MSI-H several [15] nivolumab + ipilimumab 119 55% 71% na 85% CM = CheckMate; dMMR = mismatch repair-deficient; KN = KEYNOTE; MSI-H = microsatellite instability-high; na = not available; ORR = overall response rate; OS = overall survival; PFS = progression-freesurvival. combination regimens with local ablation, chemotherapy or molecularly targeting drugs have been evaluated and a large number of trials in this setting are still ongoing. Most of these trials include all-comer populations, thus resulting in the above-mentioned proportion of dMMR/MSI-H patients. Preliminary results of some combination trials have already been presented with mixed results, although interpretation is highly limited by small numbers and missing control arms.
Local Ablation
The addition of radiotherapy or radiofrequency ablation to pembrolizumab did not yield meaningful activity with a reported 5% ORR in heavily pre-treated MCRC patients [22] . Similarly, a trial combining a PD-L2 Fc fusion protein in combination with radiotherapy did not result in relevant efficacy of this combination [23] .
Chemotherapy
Preliminary results of 2 small, single-arm trials have been presented combining chemotherapy with PD-1/L1 inhibitors with or without bevacizumab. The combination of pembrolizumab and mFOLFOX6 in 30 patients (including 3 MSI-H patients) showed an ORR of 43% and a PFS of 16.9 months [24] . The combination of atezolizumab with FOLFOX and bevacizumab yielded an ORR of 52% and PFS of 14.1 months in 23 patients [25] .
Molecularly Targeting Agents
The combination of immunotherapy and a MEK inhibitor might be of particular interest based on the upregulation of antigen presentation by MHC overexpression and increased T-cell infiltration into the tumour [26, 27] . Clinical activity could be demonstrated for the combination of cobimetinib and atezolizumab in 20 pretreated KRAS mutated patients with 4 objective responses in 3 pMMR, and 1 MMR status -unknown patient [28] . Incidence of grade 3/4 treatment-related adverse events was 35%, mainly related to the MEK inhibitor.
Ongoing Clinical Trials dMMR/MSI-H
Although several trials are ongoing, randomised phase III trials in dMMR/MSI-H are rare. In the adjuvant dMMR/MSI-H setting a phase III trial (ATOMIC) investigates the adjuvant use of atezolizumab in combination with mFOLFOX6 in lymph node positive colon cancer (stage III) (NCT02912559). For metastatic CRC, KN-177 is currently recruiting 270 previously untreated dMMR/MSI-H MCRC patients that will be treated with pembrolizumab or investigators' choice standard chemotherapy (FOLFOX or FOLFIRI, alone or in combination with bevacizumab or cetuximab) (NCT02563002). In addition, another first-line phase III trial compares atezolizumab alone with FOLFOX and bevacizumab and the combination of both (NCT02997228).
pMMR/MSS or Unselected
Based on the early efficacy data for cobimetinib and atezolizumab the consecutive phase III COTEZO trial has recruited approximately 360 patients comparing the PD-L1/MEK-inhibitor combination and atezolizumab alone versus regorafenib in a thirdline setting with results expected for mid/end 2018 (NCT02788279). The same combination is evaluated in the maintenance setting in the MODUL trial (NCT02291289). This platform trial previously included a randomised maintenance trial comparing 5FU/FS and bevacizumab with or without atezolizumab (330 patients) with the results expected for mid 2018. Other PD-L1 inhibitors (e.g. avelumab) are evaluated in the maintenance setting after cetuximab-based induction regimen in the FIRE 4 study (NCT02934529) or combined with cetuximab-based induction treatment in the AVETUX trial (NCT03174405).
Future Developments
In the very small dMMR/MSI-H subgroup, immunotherapy has been established, although confirmatory phase III data are still lacking. In contrast, for the far larger group of pMMR/MSS MCRC patients the optimal approach of integrating immunotherapy is still unknown. Beside the numerous ongoing trials in mainly unselected patients, the increasing knowledge of molecular mechanisms of distinct subtypes may pave the way for more rational combinations. For example, recent data on the correlation of CMS and immuno-signatures revealed a potentially meaningful approach of combining immunotherapy with TGF-β inhibitors particularly in CMS4 [11] . Recent preclinical research identified TGF-β as one of the relevant mechanisms of immune evasion in metastatic CRC, thus further underlining this combination approach [29] . In addition, the large number of new immunotherapeutic agents (e.g. Lag-3 or CSF1R-inhibitors) may prove useful in combination approaches in CRC. Recently, the combination of a bispecific T-cell engager (CEA-TCB) with atezolizumab has shown feasibility and preliminary efficacy [30] . Furthermore, T cell-based treatment, which is currently implemented in the treatment of leukaemia and lymphoma, may gain relevance in colorectal cancer as well [31] .
Disclosure Statement
Alexander Stein received research funding from Deutsche Krebshilfe, Sanofi, Roche, Merck, GBA Innovationsfond, BMS; advisory board fees from Sanofi, Amgen, Merck, Roche, BMS, MSD, Servier, Sirtex; speaker's fees from Sanofi, Merck, Roche, Servier, Bayer, Lilly. Gunnar Folprecht did not provide a disclosure statement.
